Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28596325 | 1.00 | USP2 (0.49) | USP2RAD52OPRD1ALDH1A1TSHR | |
| SCHEMBL22801996 | 0.88 | MAPT (0.46) | USP2RAD52OPRD1ALDH1A1TSHR | |
| SCHEMBL22801980 | 0.88 | MAPT (0.46) | USP2RAD52OPRD1ALDH1A1TSHR | |
| SCHEMBL3168784 | 0.87 | RAD52 (0.44) | USP2RAD52ALDH1A1TSHRHSD17B10 | |
| SCHEMBL5631357 | 0.87 | RAD52 (0.44) | USP2RAD52OPRD1ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL2925849 | 0.85 | RAD52 (0.46) | USP2RAD52ALDH1A1TSHRHSD17B10 | |
| SCHEMBL5742221 | 0.84 | OPRD1 (0.46) | RAD52OPRD1ALDH1A1HSD17B10MAPT | |
| SCHEMBL18889530 | 0.82 | HSD17B3 (0.43) | RAD52ALDH1A1ADRB1MAPTKMT2A | |
| SCHEMBL19617168 | 0.81 | HTT (0.49) | RAD52ALDH1A1TSHRTDP1POLB | |
| SCHEMBL22411659 | 0.81 | RAD52 (0.49) | RAD52ALDH1A1ADRB1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072521-B | ROR gamma t inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-113072521-A | ROR gamma t inhibitor and application thereof in medicine | 广东东阳光药业有限公司 | 2021-07-06 | — | — | CN | disclosed |
| WO-2018029604-A1 | C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| EP-1701960-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| CN-100469780-C | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2009-03-18 | — | — | CN | disclosed |
| US-20090023747-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| WO-2005066180-A9 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| CN-101258153-A | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| CN-1918169-A | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-1701960-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066180-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023747-A1 | Cysteine Protease Inhibitors | CTSK, CTSS, CTSZ | USP2 307/4885RAD52 3772/4885OPRD1 429/4885 |
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | USP2 826/4885RAD52 1863/4885OPRD1 810/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | USP2 840/4885RAD52 1788/4885OPRD1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.